¿Es el intervalo libre de docetaxel un factor predictivo para el cáncer de próstata resistente a la castración? |
| |
| Institution: | 1. Istanbul Medeniyet University Göztepe Education and Training Hospital, Medical Oncology Clinic, Kad?köy, ?stanbul, Turquía;2. Istanbul Medeniyet University Göztepe Education and Training Hospital, Urology Clinic, Kad?köy, ?stanbul, Turquía;3. Istanbul Kartal Lutfi Kirdar Education and Research Hospital, Medical Oncology Clinic, Kad?köy, ?stanbul, Turquía;1. Division of Anatomic Pathology and Histology, Fondazione Policlinico Universitario A. Gemelli – IRCCS, Roma, Italia;2. Università Cattolica del Sacro Cuore, Roma, Italia;1. Shu-Te University, Kaohsiung City, Taiwán;2. Department of Neurology, Kaohsiung Chang Gang Memorial Hospital, College of Medicine, Chang Gung Memorial Hospital, Kaohsiung City, Taiwán;3. Department of Clinical Forensic Medicine, Kaohsiung Medical University Hospital, College of Medicine, Kaohsiung Medical University, Kaohsiung City, Taiwán;1. Departamento de Anatomía Patológica del Hospital Reina Sofía, Tudela, Navarra;2. Departamento de Urología del Hospital Reina Sofía, Tudela, Navarra;3. Departamento de Anestesia y Reanimación del Hospital Universitario de Navarra, Pamplona, Navarra;4. TEAP del Departamento de Anatomía Patológica del Hospital Universitario de Navarra, Pamplona, Navarra |
| |
| Abstract: | ObjectiveProstate cancer (PCa) is the second most common solid tumor in men and the fifth leading cause of cancer-related death. In advanced stage, palliative treatments are used instead of curative therapies. Therefore, finding predictive indicators seems crucial. Patients with castration-resistant prostate cancer (CRPC) that received Dx chemotherapy have been retrospectively reviewed. The aim of this study was to investigate whether docetaxel (Dx)-free interval could have a predictive value for PCa and influence other sequential therapies.Material and methodsThis clinical trial study was performed on 104 patients at Medeniyet University Oncology Clinic in 2018-2020. All CRPC patients had metastases, received Dx as first-line treatment and underwent androgen receptor axis targeted (ARAT) therapy after disease progression. We analyzed patients’ progression time after Dx therapy and the effects on sequential treatment.ResultsAfter Dx therapy, all patients received ARAT (abiraterone (ABI) n: 49 (47.1%) and enzalutamide (ENZ) n: 54 (51.9%)) as a second-line treatment, except for one patient who received cabazitaxel. There was a statistically significant relationship between the Dx-free interval and duration of response to ARAT (P<.001). The response time of ARAT treatment was <10.5 months in all patients whose Dx-free interval period was <9 months.ConclusionsOur findings support the theory that Dx-free interval can be a predictive factor for CRPC. CRPC disease can be classified as Dx-sensitive disease or Dx-resistance disease, based on the Dx-free interval. Decision on subsequent treatments could be made considering this information. |
| |
| Keywords: | Castration-resistant prostate cancer Docetaxel-free interval Androgen receptor axis-targeted treatment Predictive indicator |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
